Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Assets Average (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Assets Average for 6 consecutive years, with $34.8 million as the latest value for Q4 2025.

  • Quarterly Assets Average fell 33.81% to $34.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $34.8 million through Dec 2025, down 33.81% year-over-year, with the annual reading at $30.4 million for FY2025, 44.68% down from the prior year.
  • Assets Average hit $34.8 million in Q4 2025 for Insight Molecular Diagnostics, down from $47.2 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $172.9 million in Q3 2021 to a low of $34.8 million in Q4 2025.
  • Historically, Assets Average has averaged $99.1 million across 5 years, with a median of $84.9 million in 2023.
  • Biggest five-year swings in Assets Average: soared 189.68% in 2021 and later crashed 48.5% in 2023.
  • Year by year, Assets Average stood at $164.0 million in 2021, then fell by 21.49% to $128.7 million in 2022, then tumbled by 39.22% to $78.2 million in 2023, then tumbled by 32.71% to $52.6 million in 2024, then plummeted by 33.81% to $34.8 million in 2025.
  • Business Quant data shows Assets Average for IMDX at $34.8 million in Q4 2025, $47.2 million in Q3 2025, and $55.4 million in Q2 2025.